Interferon-gamma (IFN-y) treatment or in vivo passage of the murine YAC-I lymphoma resulted in reduced sensitivity to in vitro lysis by syngeneic murine spleen cells cultured in rll-2 (LAK-cells). IFN-y treatment also rendered the murine B16 melanoma less sensitive to lysis by syngeneic LAK cells, w
Synergistic effects of co-expression of the Th1 cytokines il-2 and IFNγ on generation of murine tumor-reactive cytotoxic cells
✍ Scribed by Alexander J. McAdam; Beth A. Pulaski; Stephanie S. Harkins; Elizabeth K. Hutter; Edith M. Lord; John G. Frelinger
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 785 KB
- Volume
- 61
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
While the effect of cytokines on the generation of tumor‐reactive cytotoxic cells has been a topic of active investigation, the effect of physiological cytokine combinations has not been determined. We have investigated the effect of co‐expression of IL‐2 and IFN‐γ on the generation of cytotoxic cells against the murine line 1 tumor in vivo. These cytokines were selected because they are normally produced in concert by a subset of T‐helper cells called T‐helper 1 (Th1). We transfected the line 1 murine carcinoma with cDNA for IL‐2 and IFN‐γ, alone or combined. IFN‐γ alone does not elicit rejection of the transfectant, but IL‐2 increases the tumorigenic dose by 10,000‐fold above the parental cells. Co‐expression of IFN‐γ and IL‐2 increases this rejection to at least 100,000‐fold above parental line 1. Unlike IL‐2 transfectants, tumor cells expressing both IFN‐γ and IL‐2 can also elicit rejection of admixed parental tumor cells. Finally, the IFN‐γ/IL‐2 transfectants are more effective at generating memory cells that are cytolytic for the parental tumor. Our results show that synergistic interactions of Th1 cytokines can remarkably enhance the cytotoxic response to tumors. © 1995 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
The human § -chemokine receptor fusin/CXCR4 is an important cofactor for entry of T lymphocyte-tropic HIV-1 strains. We investigated the possible regulatory role of T cell cytokine patterns on CXCR4 as well as HIV expression by using in vitro models of both secondary and primary immune responses. An
Therapy with IL-12 or IL-2 induces tumor regression in only a few patients with head-and-neck squamous cell carcinoma (SCC), and the factors promoting responsiveness have not been well defined. In this study, we examined whether combined IL-12 and IL-2 therapy can induce tumor regression in a new mu